Antisecretory Factor During Concomitant and Adjuvant Therapy of Primary Glioblastoma, a Randomised, Prospective and Double Blinded Study

Trial ID: NCT05669820

Interventional - Phase 2/3 - Recruiting

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

Conditions

• Glioblastoma

Interventions

• Salovum
• Placebo egg yolk powder

Eligibility

Inclusion criteria

• 1. Pathology verified glioblastoma or astrocytoma grade 4
• 2. Age 18-75 years
• 3. Surgical treatment-resection.
• 4. Scheduled concomitant radiochemotherapy, or only chemotherapy.
• 5. Informed consent

Exclusion criteria

• 1. No informed consent
• 2. Egg yolk allergy
• 3. Only surgical biopsy
• 4. Only radiotherapy

Sponsor

Peter Siesjö, Lund University

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows